New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
复制标题
DOI：
10.1158/1078-0432.ccr-09-2029
复制
发表时间：
2010-06-01
影响因子：
11.5
通讯作者：
Van Cutsem, Eric
中科院分区：
文献类型：
--
作者：
Prenen, Hans;Tejpar, Sabine;Van Cutsem, Eric
新的细胞毒剂和新的靶向治疗方法的引入大大拓宽了转移性结直肠癌(CRC)患者的治疗选择和预后。抗表皮生长因子受体(EGFR)抗体的引入，西妥昔单抗和帕尼图单抗，显然促进了这一发展。KRAS作为抗EGFR抗体耐药标志物的概念已经得到验证。然而，新的挑战也出现了：对KRAS在肿瘤生长过程中的关键和核心作用的全面了解，以及对KRAS突变肿瘤的新治疗策略的开发。KRAS似乎是如此关键，因此可能需要对KRAS野生型和突变型进行进一步的分类和描述。因此，KRAS突变检测标志着转移性结直肠癌治疗模式的转变。这项测试还强调了对KRAS突变型转移性结直肠癌新治疗选择的需求尚未得到满足。在这篇综述中，我们将重点介绍这些患者可能的新治疗方案。临床癌症资源；16(11)；2921-6。(C)2010年AACR。
The introduction of new cytotoxic agents and new targeted therapies has significantly broadened the therapeutic options for and the outcomes of patients with metastatic colorectal cancer (CRC). The introduction of the anti-epidermal growth factor receptor (EGFR) antibodies, cetuximab and panitumumab, has clearly contributed to this development. The concept of KRAS as a marker for resistance to anti-EGFR antibodies has been validated. However, new challenges have emerged: the complete understanding of the crucial and central role of KRAS in processes of tumor growth and the development of new treatment strategies for KRAS mutant tumors. KRAS seems to be so crucial that a further classification and description in KRAS wild-type and mutant may be warranted. Testing for KRAS mutations marks, therefore, a paradigm shift in the management of metastatic CRC. This testing also highlights the unmet need for new treatment options in KRAS mutant metastatic CRC. In this review we will focus on possible new treatment options for these patients. Clin Cancer Res; 16(11); 2921-6. (C) 2010 AACR.